Literature DB >> 16484585

The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy.

Lesley A Simpson1, Emily A Burwell, Kida A Thompson, Samira Shahnaz, Allen R Chen, David M Loeb.   

Abstract

Previous work has demonstrated that WT1 (-Ex5/-KTS) potentiates granulocyte colony-stimulating factor (G-CSF)-mediated granulocytic differentiation. This WT1 isoform suppresses cyclin E, which may contribute to the prodifferentiation effect by slowing proliferation, but WT1 target genes that affect survival might also be involved. We screened a cDNA array and identified the bCL2 family member A1/BFL1 as a new WT1 target gene in 32D cl3 murine myeloblast cells. Induction of WT1 (-Ex5/-KTS) expression is accompanied by up-regulation of A1 on the cDNA array, and this up-regulation was confirmed by semiquantitative reverse transcription-polymerase chain reaction (RT-PCR). Moreover, both promoter-reporter assays and chromatin immunoprecipitation assays suggest that this isoform of WT1 activates the promoter directly. Constitutive expression of A1 in 32D cl3 cells induces spontaneous granulocytic differentiation, with both morphologic and cell-surface antigen changes, as well as resistance both to chemotherapy and to withdrawal of interleukin-3 (IL-3). Finally, we note an association between WT1 expression and A1 expression in primary acute myeloid leukemia samples. Taken together, these results demonstrate that A1 is a new WT1 target gene involved in both granulocytic differentiation and resistance to cell death, and suggests that these genes might play an important role in the biology of high-risk leukemias.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16484585      PMCID: PMC1895805          DOI: 10.1182/blood-2005-10-4025

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Cyclin E is a target of WT1 transcriptional repression.

Authors:  David M Loeb; Dorian Korz; Michael Katsnelson; Emily A Burwell; Alan D Friedman; Saraswati Sukumar
Journal:  J Biol Chem       Date:  2002-03-27       Impact factor: 5.157

2.  WT-1 is required for early kidney development.

Authors:  J A Kreidberg; H Sariola; J M Loring; M Maeda; J Pelletier; D Housman; R Jaenisch
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

3.  WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.

Authors:  K Inoue; H Sugiyama; H Ogawa; M Nakagawa; T Yamagami; H Miwa; K Kita; A Hiraoka; T Masaoka; K Nasu
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

4.  Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping.

Authors:  M Gessler; A Poustka; W Cavenee; R L Neve; S H Orkin; G A Bruns
Journal:  Nature       Date:  1990-02-22       Impact factor: 49.962

5.  Alternative splicing and genomic structure of the Wilms tumor gene WT1.

Authors:  D A Haber; R L Sohn; A J Buckler; J Pelletier; K M Call; D E Housman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

6.  Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1.

Authors:  I A Drummond; S L Madden; P Rohwer-Nutter; G I Bell; V P Sukhatme; F J Rauscher
Journal:  Science       Date:  1992-07-31       Impact factor: 47.728

7.  Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2.

Authors:  E Y Lin; A Orlofsky; M S Berger; M B Prystowsky
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

8.  An isoform of the Wilms' tumor suppressor gene potentiates granulocytic differentiation.

Authors:  D M Loeb; J L Summers; E A Burwell; D Korz; A D Friedman; S Sukumar
Journal:  Leukemia       Date:  2003-05       Impact factor: 11.528

9.  A second transcriptionally active DNA-binding site for the Wilms tumor gene product, WT1.

Authors:  Z Y Wang; Q Q Qiu; K T Enger; T F Deuel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

10.  Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing.

Authors:  S H Larsson; J P Charlieu; K Miyagawa; D Engelkamp; M Rassoulzadegan; A Ross; F Cuzin; V van Heyningen; N D Hastie
Journal:  Cell       Date:  1995-05-05       Impact factor: 41.582

View more
  25 in total

Review 1.  BCL2A1: the underdog in the BCL2 family.

Authors:  M Vogler
Journal:  Cell Death Differ       Date:  2011-11-11       Impact factor: 15.828

2.  T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.

Authors:  Elaine M Sloand; J Joseph Melenhorst; Zachary C G Tucker; Loretta Pfannes; Jason M Brenchley; Agnes Yong; Valeria Visconte; Colin Wu; Emma Gostick; Phillip Scheinberg; Matthew J Olnes; Daniel C Douek; David A Price; A John Barrett; Neal S Young
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

3.  P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).

Authors:  Zhongyan Hua; Yue Zhan; Simeng Zhang; Yudi Dong; Min Jiang; Fei Tan; Zhihui Liu; Carol J Thiele; Zhijie Li
Journal:  Apoptosis       Date:  2018-08       Impact factor: 4.677

4.  WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia.

Authors:  Gregory McCarty; Ola Awad; David M Loeb
Journal:  J Biol Chem       Date:  2011-10-26       Impact factor: 5.157

Review 5.  WT1 Alternative Splicing: Role of Its Isoforms in Neuroblastoma.

Authors:  Daniela Maria Rasà; Agata Grazia D'Amico; Grazia Maugeri; Sebastiano Cavallaro; Velia D'Agata
Journal:  J Mol Neurosci       Date:  2017-05-22       Impact factor: 3.444

6.  HtrA2, taming the oncogenic activities of WT1.

Authors:  Jörg Hartkamp; Stefan G E Roberts
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

Review 7.  Tumour-associated antigens: considerations for their use in tumour immunotherapy.

Authors:  Adam J Linley; Murrium Ahmad; Robert C Rees
Journal:  Int J Hematol       Date:  2011-03-01       Impact factor: 2.490

8.  The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xL.

Authors:  Hima Bansal; Theresea Seifert; Carlos Bachier; Manjeet Rao; Gail Tomlinson; Swaminathan Padmanabhan Iyer; Sanjay Bansal
Journal:  J Biol Chem       Date:  2012-08-16       Impact factor: 5.157

9.  The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi.

Authors:  Jörg Hartkamp; Brian Carpenter; Stefan G E Roberts
Journal:  Mol Cell       Date:  2010-01-29       Impact factor: 17.970

10.  Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.

Authors:  Qiu-Sha Huang; Jing-Zhi Wang; Ya-Zhen Qin; Qiao-Zhu Zeng; Qian Jiang; Hao Jiang; Jin Lu; Hui-Xin Liu; Yi Liu; Jing-Bo Wang; Li Su; Hong-Yu Zhang; Zhen-Ling Li; Su-Jun Gao; Bo Huang; Yu-Ying Liu; Yan-Rong Liu; Lan-Ping Xu; Xiao-Jun Huang; Xiao-Hui Zhang
Journal:  Blood Adv       Date:  2019-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.